Cargando…

Milano Policlinico ONCOVID modified Score for risk evaluation in oncology during the COVID-19 pandemic: a prospective monocentric study

PURPOSE: Due to their immunosuppressed status, patients with cancer have been reported to be at increased risk of COVID-19 infection. We aimed to assess the prevalence of COVID-19 in patients with cancer and to identify its risk factors. METHODS: A prospective study was conducted at the Department o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ben Kridis, Wala, Lajnef, Maissa, Khmeri, Souhir, Khanfir, Afef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995143/
https://www.ncbi.nlm.nih.gov/pubmed/35399105
http://dx.doi.org/10.1007/s00520-022-07040-3
_version_ 1784684250579075072
author Ben Kridis, Wala
Lajnef, Maissa
Khmeri, Souhir
Khanfir, Afef
author_facet Ben Kridis, Wala
Lajnef, Maissa
Khmeri, Souhir
Khanfir, Afef
author_sort Ben Kridis, Wala
collection PubMed
description PURPOSE: Due to their immunosuppressed status, patients with cancer have been reported to be at increased risk of COVID-19 infection. We aimed to assess the prevalence of COVID-19 in patients with cancer and to identify its risk factors. METHODS: A prospective study was conducted at the Department of Medical oncology of Sfax from November 2020 to February 2021. We analyzed data of 226 patients treated for solid cancer. We used the Milano Policlinico ONCOVID modified Score to quantify the risk of infection in patients with cancer. RESULTS: Patients aged less than 70 years represented 85%. The most common primary tumors were breast cancer (37%) and colorectal cancer (22%). Comorbidities were observed in 39% of cases. Among 226 patients with cancer, 19 patients (8.4%) had COVID-19 disease. In 42% of cases, patients were under chemotherapy and 63% of them have a metastatic disease. Fifteen patients (79%) were symptomatic. A severe form of COVID-19 requiring hospitalization was seen in 4 patients (21%). Of 19 patients who tested positive for COVID-19, 47% had an intermediate and high risk of infection. COVID-19 infection was correlated with intermediate or high risk (p = 0.018), age < 70 years (p = 0.035), and chemotherapy treatment (p = 0.032). In multivariable analysis, only the intermediate or high risk were correlated with COVID-19 infection in cancer patient (p = 0.025). CONCLUSION: This study concluded that using the Milano Policlinico ONCOVID modified Score is very helpful for clinicians to identify vulnerable patients and to make the appropriate decision in the management of cancer patients.
format Online
Article
Text
id pubmed-8995143
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-89951432022-04-11 Milano Policlinico ONCOVID modified Score for risk evaluation in oncology during the COVID-19 pandemic: a prospective monocentric study Ben Kridis, Wala Lajnef, Maissa Khmeri, Souhir Khanfir, Afef Support Care Cancer Original Article PURPOSE: Due to their immunosuppressed status, patients with cancer have been reported to be at increased risk of COVID-19 infection. We aimed to assess the prevalence of COVID-19 in patients with cancer and to identify its risk factors. METHODS: A prospective study was conducted at the Department of Medical oncology of Sfax from November 2020 to February 2021. We analyzed data of 226 patients treated for solid cancer. We used the Milano Policlinico ONCOVID modified Score to quantify the risk of infection in patients with cancer. RESULTS: Patients aged less than 70 years represented 85%. The most common primary tumors were breast cancer (37%) and colorectal cancer (22%). Comorbidities were observed in 39% of cases. Among 226 patients with cancer, 19 patients (8.4%) had COVID-19 disease. In 42% of cases, patients were under chemotherapy and 63% of them have a metastatic disease. Fifteen patients (79%) were symptomatic. A severe form of COVID-19 requiring hospitalization was seen in 4 patients (21%). Of 19 patients who tested positive for COVID-19, 47% had an intermediate and high risk of infection. COVID-19 infection was correlated with intermediate or high risk (p = 0.018), age < 70 years (p = 0.035), and chemotherapy treatment (p = 0.032). In multivariable analysis, only the intermediate or high risk were correlated with COVID-19 infection in cancer patient (p = 0.025). CONCLUSION: This study concluded that using the Milano Policlinico ONCOVID modified Score is very helpful for clinicians to identify vulnerable patients and to make the appropriate decision in the management of cancer patients. Springer Berlin Heidelberg 2022-04-11 2022 /pmc/articles/PMC8995143/ /pubmed/35399105 http://dx.doi.org/10.1007/s00520-022-07040-3 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Ben Kridis, Wala
Lajnef, Maissa
Khmeri, Souhir
Khanfir, Afef
Milano Policlinico ONCOVID modified Score for risk evaluation in oncology during the COVID-19 pandemic: a prospective monocentric study
title Milano Policlinico ONCOVID modified Score for risk evaluation in oncology during the COVID-19 pandemic: a prospective monocentric study
title_full Milano Policlinico ONCOVID modified Score for risk evaluation in oncology during the COVID-19 pandemic: a prospective monocentric study
title_fullStr Milano Policlinico ONCOVID modified Score for risk evaluation in oncology during the COVID-19 pandemic: a prospective monocentric study
title_full_unstemmed Milano Policlinico ONCOVID modified Score for risk evaluation in oncology during the COVID-19 pandemic: a prospective monocentric study
title_short Milano Policlinico ONCOVID modified Score for risk evaluation in oncology during the COVID-19 pandemic: a prospective monocentric study
title_sort milano policlinico oncovid modified score for risk evaluation in oncology during the covid-19 pandemic: a prospective monocentric study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995143/
https://www.ncbi.nlm.nih.gov/pubmed/35399105
http://dx.doi.org/10.1007/s00520-022-07040-3
work_keys_str_mv AT benkridiswala milanopoliclinicooncovidmodifiedscoreforriskevaluationinoncologyduringthecovid19pandemicaprospectivemonocentricstudy
AT lajnefmaissa milanopoliclinicooncovidmodifiedscoreforriskevaluationinoncologyduringthecovid19pandemicaprospectivemonocentricstudy
AT khmerisouhir milanopoliclinicooncovidmodifiedscoreforriskevaluationinoncologyduringthecovid19pandemicaprospectivemonocentricstudy
AT khanfirafef milanopoliclinicooncovidmodifiedscoreforriskevaluationinoncologyduringthecovid19pandemicaprospectivemonocentricstudy